• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    How Earnings Turnaround And FX-Hit Outlook At Integra LifeSciences (IART) Has Changed Its Investment Story

    Simply Wall St·08/10/2026 00:27:42
    Listen to the news
    • Integra LifeSciences Holdings Corporation reported past second-quarter 2026 results showing sales of US$418.76 million and net income of US$4.48 million, a shift from a large net loss a year earlier.
    • The company also modestly reduced its full-year 2026 reported revenue outlook due to currency headwinds while reaffirming its organic revenue growth and adjusted EPS guidance, underscoring the effect of foreign exchange on reported performance.
    • We’ll now examine how this earnings improvement, alongside currency-adjusted full-year guidance, shapes Integra LifeSciences’ broader investment narrative.

    This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.

    What Is Integra LifeSciences Holdings' Investment Narrative?

    To own Integra LifeSciences today, you need to believe the business can turn a lengthy stretch of losses into consistent profitability while managing execution and regulatory risk. The latest quarter helps that case: revenue ticked higher and the company swung from a very large loss to a small profit, while management only trimmed full-year reported revenue guidance for currency effects and kept its organic growth and adjusted EPS targets intact. That suggests the biggest near-term drivers still center on operational execution, product relaunches like SurgiMend and the refreshed commercial and regulatory leadership team, rather than on demand falling away. At the same time, ongoing product recalls and a balance sheet where interest costs are not well covered by earnings remain key pressure points that this improving quarter has not fully resolved.

    However, one operational issue in particular could still weigh heavily on Integra’s margin recovery. Integra LifeSciences Holdings' shares have been on the rise but are still potentially undervalued by 47%. Find out what it's worth.

    Exploring Other Perspectives

    IART 1-Year Stock Price Chart
    IART 1-Year Stock Price Chart
    Two Simply Wall St Community fair value estimates, between US$27.00 and about US$32.54, show how widely private investors can size Integra’s potential, even as recent recalls and thin profitability keep execution risk firmly in view.

    Explore 2 other fair value estimates on Integra LifeSciences Holdings - why the stock might be worth as much as 89% more than the current price!

    Form Your Own Verdict

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    Want Some Alternatives?

    These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.